Skip to Content

Join the 'Lysosomal Acid Lipase Deficiency' group to help and get support from people like you.

Lysosomal Acid Lipase Deficiency News

Related terms: Wolman's Disease

Kanuma Approved for Rare Missing-Enzyme Disease

Posted 12 Dec 2015 by

TUESDAY, Dec. 8, 2015 – Kanuma (sebelipase alfa) has been approved by the U.S. Food and Drug Administration as the first treatment for a rare but often-deadly disease caused by an enzyme deficiency. People with Lal deficiency, also known as Wolman disease or cholesteryl ester storage disease, produce little or none of the enzyme lysosomal acid lipase (Lal). This causes fat buildup in the body that can lead to life-threatening liver or heart problems. The disease, affecting up to two people per million births, is commonly diagnosed during the first two-to-four months of infancy, the FDA said in a news release. Life expectancy depends on the disease's severity and its complications, the agency said. Kanuma is human Lal that's produced by genetically modified chickens in their egg whites. Neither the chicken or its eggs are allowed in the food supply, the FDA said. The injected drug is ... Read more

Related support groups: Kanuma, Lysosomal Acid Lipase Deficiency, Sebelipase Alfa

Ask a Question

Further Information

Related Drug Support Groups

Kanuma, sebelipase alfa